Korea A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new 300-million-euro plant; EuBiologics’s World Health Organization (WHO) prequalification for its cholera vaccine, and Samsung Biologics’ record Q1 earnings. South…
South Korea Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal with the shortage, the government has created a plan to boost the yearly number of medical students, but this has…
APAC The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to shorter reimbursement timelines; Novartis’ early-stage HDAC6 Inhibitor deal with Chong Kun Dang Pharmaceutical; Astellas Pharma’s gastric cancer FDA fail; Daiichi…
Korea Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. The acquisition deal, as reported by Hyun-Ah Oh from Korea Economic Daily, involves the purchase of all shares held by…
Korea A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation hub in Boston, US; a list of some of the country’s most important biotech companies; and Medtronic’s move to purchase…
South Korea As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top CDMO organizations, with revenues of USD 1.21 billion in 2021, is no exception. In response to increased demand, the firm…
Chile Korean biotech SK Bioscience, known for bringing forward the first South Korean-developed COVID-19 vaccine, is pursuing its beyond-COVID growth strategy with a new green light for its SKYCellflu vaccine. The recent approval by Chile’s Instituto de Salud Publica follows nine others and is the first in the Latin America region.…
Korea While the Korean medical device market dropped in size in 2020 as a result of the COVID-19 pandemic, it rebounded in 2021 to reach a record breaking height of USD 7.9 billion. Local production and exports are also experiencing significant year-on-year growth rates, as the below chart shows. Made…
South Korea After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already securely anchored in the American life sciences ecosystem: former senior program officer in global health at the Bill & Melinda…
Korea SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. Back in October 2021, PharmaBoardroom ran through the leading Korean companies in the race to develop a homegrown vaccine against…
South Korea ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and medical aesthetics. He walks us through ExoCoBio’s exosome-based finished product line as well as its promising preclinical findings not just…
South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…
See our Cookie Privacy Policy Here